ReviewNature reviews. Endocrinology2011
Pathogenesis of pituitary tumors.
Review in Nature reviews. Endocrinology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02160730 (Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine), which is not on this map. Cited by 202 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine
Who cites it
202 citing papers in PubMed, 7 syntheses or guidelines pooled it, 462 citations in OpenAlex.
- Clinical characteristics associated with somaticFrontiers in endocrinology · 2026Pooled it
- The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review.International journal of molecular sciences · 2023Pooled it
- A systematic review of molecular alterations in invasive non-functioning pituitary adenoma.Endocrine · 2022Pooled it
- Use of optical fluorescence agents during surgery for pituitary adenomas: current state of the field.Journal of neuro-oncology · 2019Pooled it
- Gene expression in prolactinomas: a systematic review.Pituitary · 2016Pooled it
- Correlations of pituitary tumor transforming gene expression with human pituitary adenomas: a meta-analysis.PloS one · 2014Pooled it
- Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of giant pituitary adenomas.Pituitary · 2012Pooled it
- Trial
- HMGA proteins in the nervous system: role in brain tumorigenesis and neurodegeneration.Cell death discovery · 2026Review
- Extracellular Vesicle-Mediated Communication in Sellar Tumors: A Conceptual and Translational Framework.International journal of molecular sciences · 2026Review
- Cardiac Tamponade, Pituitary Hyperplasia, and Macroorchidism in Severe Primary Hypothyroidism.JCEM case reports · 2026Article
- Unifying regulatory motifs in endocrine circuits.Nature communications · 2025Article
- Insulin signalling-associated cell fate promotes neoplastic invasiveness in non-functioning pituitary gonadotroph adenoma via cis-regulatory elements activation.British journal of cancer · 2025Article
- DNA methylation profiling of pituitary neuroendocrine tumors identifies distinct clinical and pathological subtypes based on epigenetic differentiation.Neuro-oncology · 2025Article
- The Roles of PD-L1, Ki-67, P53, and Cyclin D1 in PitNETs: Diagnostic and Prognostic Implications in a Series of 74 Patients.International journal of molecular sciences · 2025Article
- Challenges and opportunities for new intraoperative optical techniques in the surgical treatment of pituitary adenomas: a review.Journal of biomedical optics · 2025Review
- MRI based radiomics nomogram for predict recurrence of non functioning pituitary macroadenomas post surgery.Scientific reports · 2025Article
- Article
- TRIM21-mediated ubiquitination and phosphorylation of ERK1/2 promotes cell proliferation and drug resistance in pituitary adenomas.Neuro-oncology · 2025Article
- Relationship between Pituitary Gland and Stem Cell in the Aspect of Hormone Production and Disease Prevention: A Narrative Review.Endocrine, metabolic & immune disorders drug targets · 2025Review
142 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary adenomas may hypersecrete hormones (including prolactin, growth hormone and adrenocorticotropic hormone, and rarely follicle-stimulating hormone, luteinizing hormone or TSH) or may be nonfunctional. Despite their high prevalence in the general population, these tumors are invariably benign and exhibit features of differentiated pituitary cell function as well as premature proliferative arrest. Pathogenesis of dysregulated pituitary cell proliferation and unrestrained hormone hypersecretion may be mediated by hypothalamic, intrapituitary and/or peripheral factors. Altered expression of pituitary cell cycle genes, activation of pituitary selective oncoproteins or loss of pituitary suppressor factors may be associated with aberrant growth factor signaling. Considerable information on the etiology of these tumors has been derived from transgenic animal models, which may not accurately and universally reflect human tumor pathophysiology. Understanding subcellular mechanisms that underlie pituitary tumorigenesis will enable development of tumor aggression markers as well as novel targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.